Group 1 - The National Medical Products Administration has accepted the application for Patheon Inc.'s Paracetamol Sorbitol Calcium Oral Suspension, with acceptance number JTH2600030, on February 9, 2026 [1] - The drug is classified as a chemical drug under the registration type [1] - The application involves multiple companies, including Patheon Inc., Vifor Fresenius Medical Care Renal Pharma France, and Fortune Pharma Research (Beijing) Co., Ltd. [1] Group 2 - Fortune Pharma Research (Beijing) Co., Ltd. was established on January 20, 2005, and is a foreign-owned limited liability company engaged in medical research and experimental development [1] - The company has a registered capital of 6.8 million USD and a paid-in capital of 4.4 million USD, with 207 insured employees [1] - The sole shareholder, FORTREA ASIA-PACIFIC INC., holds 100% of the shares, with a subscribed capital contribution of 6.8 million USD made on September 16, 2015 [1]
药物受理最新动态：Patheon Inc.帕替罗姆山梨醇钙口服混悬剂申请获受理
Xin Lang Cai Jing·2026-02-09 06:21